Cargando…
Advances in Targeting HER3 as an Anticancer Therapy
HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of H...
Autores principales: | Jiang, Ning, Saba, Nabil F., Chen, Zhuo Georgia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502787/ https://www.ncbi.nlm.nih.gov/pubmed/23198146 http://dx.doi.org/10.1155/2012/817304 |
Ejemplares similares
-
The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
por: Chen, Zhuo Georgia, et al.
Publicado: (2022) -
HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018) -
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009) -
History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
por: Ariga, Shin
Publicado: (2023) -
Targeting senescence as an anticancer therapy
por: Bousset, Laura, et al.
Publicado: (2022)